Rika Yuliwulandari
Overview
Explore the profile of Rika Yuliwulandari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuliwulandari R, Prayuni K, Viyati K, Mahasirimongkol S, Wichukchinda N
Heliyon
. 2024 Mar;
10(5):e26713.
PMID: 38439829
Background: The alleles have been used as a marker to predict drug-induced adverse reactions and as a major contributor to hypersensitivity reactions. We examined the feasibility of alleles as pharmacogenomic...
2.
Soedarsono S, Jayanti R, Mertaniasih N, Kusmiati T, Permatasari A, Indrawanto D, et al.
Tuberculosis (Edinb)
. 2023 Feb;
139:102325.
PMID: 36841141
Background: Interindividual variability in the pharmacokinetics (PK) of anti-tuberculosis (TB) drugs is the leading cause of treatment failure. Herein, we evaluated the influence of demographic, clinical, and genetic factors that...
3.
Ningrum V, Sadewa A, Ikawati Z, Yuliwulandari R, Ikhsan M, Fajriyah R
PLoS One
. 2022 Jul;
17(7):e0271410.
PMID: 35905099
Interindividual variation is important in the response to metformin as the first-line therapy for type-2 diabetes mellitus (T2DM). Considering that OCT1 and MATE1 transporters determine the metformin pharmacokinetics, this study...
4.
Soedarsono S, Jayanti R, Mertaniasih N, Kusmiati T, Permatasari A, Indrawanto D, et al.
Int J Infect Dis
. 2022 Jan;
117:8-14.
PMID: 35017103
Objectives: No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB). Therefore, we aimed to develop a population PK model to optimize...
5.
Yuliwulandari R, Shin J, Kristin E, Suyatna F, Prahasto I, Prayuni K, et al.
Pharmacogenomics J
. 2021 Apr;
21(4):476-483.
PMID: 33824430
Carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are strongly associated with the HLA-B*15:02 allele. Screening HLA-B*15:02 before CBZ administration might prevent CBZ-induced SJS/TEN by enabling clinicians to prescribe...
6.
Runcharoen C, Fukunaga K, Sensorn I, Iemwimangsa N, Klumsathian S, Tong H, et al.
Hum Genome Var
. 2021 Feb;
8(1):7.
PMID: 33542200
Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. Next-generation sequencing (NGS) is a cost-effective technology...
7.
Yuliwulandari R, Prayuni K, Razari I, Susilowati R, Zulhamidah Y, Soedarsono S, et al.
Pharmacogenomics
. 2021 Jan;
22(3):157-163.
PMID: 33399479
Owing to the high resistance rate of tuberculosis (TB) to isoniazid, which is metabolized by -acetyltransferase 2 (NAT2), we investigated the associations between variants and multidrug-resistant (MDR)-TB. The acetylator status...
8.
Soedarsono S, Amin M, Tokunaga K, Yuliwulandari R, Suameitria Dewi D, Mertaniasih N
Int J Mycobacteriol
. 2020 Dec;
9(4):380-390.
PMID: 33323653
Background: The disease severity in pulmonary Multidrug-resistant tuberculosis (MDR-TB) varies from mild to severe, which is determined by host and pathogen virulence factors. The difference of symptoms felt by TB...
9.
Yuliwulandari R, Prayuni K, Susilowati R, Sofro A, Tokunaga K, Shin J
Pharmacogenomics
. 2019 Nov;
20(18):1303-1311.
PMID: 31699005
We investigated the contribution of NAT2 variants and acetylator status to anti-tuberculosis drug-induced liver injury (AT-DILI) severity. 100 patients with clinically severe AT-DILI and 210 non-AT-DILI controls were subjected to...
10.
Chumnumwat S, Lu Z, Sukasem C, Winther M, Capule F, Abdul Hamid A, et al.
Public Health Genomics
. 2019 Oct;
22(3-4):132-139.
PMID: 31587001
Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation...